In Brief: Nexell Therapeutics
This article was originally published in The Gray Sheet
Executive Summary
Nexell Therapeutics: Baxter/VimRx cell therapy joint venture submits a premarket approval application supplement to a pending PMA for the Isolex 300 semi-automated stem cell selection system. The supplement requests FDA review of the firm's Isolex 300i fully automated system, which, like the Isolex 300, is intended for enrichment of CD34+ cells and the reduction of non-target (non CD34+) cells in cryopreserved autologous peripheral blood stem cell products that are reinfused into patients undergoing autologous peripheral blood transplantation. The transplantation procedure is used to restore a patient's blood and immune system following high-dose chemotherapy. Data in support of the PMA supplement was submitted to FDA from three separate trials, one of which involved 114 patients (92 randomized) with high risk or advanced breast cancer. During a review of the original Isolex submission in July, FDA's Biological Response Modifiers Advisory Committee did not take a formal vote on the PMA, but did agree that study data demonstrated efficacy ("The Gray Sheet" July 28, 1997, p. 8)...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.